Kinase bypass: A new strategy for anti-HIV drug design

Kinase bypass: A new strategy for anti-HIV drug design Successful kinase bypass with new acyclovir phosphoramidate prodrugs Aryl phosphate derivates of AZT inhibit HIV replication in cells where the nucleoside is poorly active Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells The Application of Phosphoramidate Protide Technology to Acyclovir Confers Anti-HIV Inhibition Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT S-Acyl-2-thioethyl Phosphoramidate Diester Derivatives as Mononucleotide Prodrugs Aryl nucleoside H-phosphonates. Part 16: Synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters